Stephanie Moore, MD
Advanced Heart Failure and Transplant Cardiology · Boston, MANPI 1740261486
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $25,720 of the $30,130 with a category attached, or 85.4%. Boehringer Ingelheim accounts for 70.5% of it on its own, with 25 other manufacturers making up the rest.
Across 180 payments — averaging $167.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$21K
- Lilly USA, LLC$5K
- Abiomed$569
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$459
- Abbott$376
- Actelion Pharmaceuticals US, Inc.$267
- plus $2K from 20 others
What the payments were for
- Speaking & faculty fees$25,72085%
- Food & beverage$4,41015%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 32 | $21,235 |
| Lilly USA, LLC | 5 | $5,200 |
| Abiomed | 10 | $569 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 16 | $459 |
| Abbott | 11 | $376 |
| Actelion Pharmaceuticals US, Inc. | 13 | $267 |
| Alnylam Pharmaceuticals Inc. | 11 | $251 |
| AstraZeneca | 9 | $244 |
| E.r. Squibb & Sons, L.L.C. | 13 | $218 |
| Merck | 10 | $177 |
| Vifor Pharma, Inc. | 8 | $171 |
| Medtronic | 4 | $141 |
| Daxor Corporation | 2 | $129 |
| Pfizer | 6 | $121 |
| Novo Nordisk | 7 | $119 |
| Novartis | 6 | $101 |
| Lexicon Pharmaceuticals, Inc. | 3 | $76 |
| Bayer | 3 | $53 |
| Impulse Dynamics (USA) Inc. | 2 | $51 |
| Cvrx, Inc. | 3 | $43 |
| Bsn Medical Inc | 1 | $24 |
| Johnson & Johnson | 1 | $23 |
| Medline Industries LP | 1 | $23 |
| Baxter Healthcare | 1 | $22 |
| Masimo Corporation | 1 | $21 |
| Boston Scientific | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$30,130 in reported general payments places this provider in the 75th percentile of 35 advanced heart failure and transplant cardiology providers in Massachusetts.
See all advanced heart failure and transplant cardiology providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CresembaIsavuconazonium Sulfate | 15 | $115,620 |
| EntrestoSacubitril/Valsartan | 26 | $36,834 |
| EliquisApixaban | 15 | $19,912 |
| Valganciclovir Hcl | 22 | $9,623 |
| Bumetanide | 22 | $1,487 |
| Mycophenolate Mofetil | 13 | $962 |
| Metoprolol Succinate | 30 | $412 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 23 | $215 |
| Pravastatin Sodium | 13 | $214 |
| Spironolactone | 22 | $141 |
| Pantoprazole Sodium | 13 | $108 |
| ClopidogrelClopidogrel Bisulfate | 12 | $100 |
| Amlodipine Besylate | 36 | $94 |
| Losartan Potassium | 13 | $65 |
| Atorvastatin Calcium | 17 | $53 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $101 | $36,83426 claims |
| PfizerEliquis | $121 | $19,91215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 35 advanced heart failure and transplant cardiology providers in Massachusetts.
Other advanced heart failure and transplant cardiology in Boston
- Pablo Quintero PinzonBoston$137K
- Daniel ZlotoffBoston$96K
- Christina Vander PluymBoston$55K
- Monica AhluwaliaBoston$39K
- David DenofrioBoston$18K
- Robb KociolBoston$12K
- Marwa SabeBoston$12K
- Edward GrandinBoston$8K
- Kemar BrownBoston$7K
- Kevin DalyBoston$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.